# Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

## TL;DR

A patient with refractory thymic carcinoma experienced a long-lasting response to third-line immunotherapy with sintilimab, showing it could be a viable treatment option.

## Contribution

Demonstrates the potential of third-line sintilimab treatment for refractory thymic carcinoma.

## Key findings

- A TC patient achieved 17 months of partial remission with third-line sintilimab.
- The treatment was well-tolerated with no serious side effects.
- Sintilimab shows promise as a therapeutic option for refractory TC patients.

## Abstract

Thymic carcinoma (TC) is an uncommon type of thymic epithelial tumors. Patients with relapsed or refractory TCs have a poor prognosis. Immune checkpoint inhibitor monotherapy can be applied as a second-line treatment for such cases. This study reported a TC patient who did not respond to conventional chemotherapy and radiotherapy but achieved prolonged partial remission lasting 17 months following the third-line treatment with anti-programmed cell death-1 inhibitor sintilimab. This patient did not experience any serious side effects associated with sintilimab treatment. The above results demonstrated that sintilimab could be a feasible therapeutic option for refractory TC patients.